Document:

coll_Ex10_5

		
			Exhibit 10.5
		

		
			SEVENTH AMENDMENT
		

		
			TO
		

		
			LOAN AND SECURITY AGREEMENT
		

		
			This Seventh Amendment to Loan and Security Agreement (this “Amendment”) is entered into this [______] day of [_____],  2018, by and between SILICON VALLEY BANK, a California corporation with a loan production office located at 275 Grove Street, Suite 2-200, Newton, Massachusetts 02466 (“Bank”) and COLLEGIUM PHARMACEUTICAL, INC., a Virginia corporation with an office located at 780 Dedham Street, Suite 800, Canton, Massachusetts 02021 (“Borrower”).
		

		
			RECITALS
		

		
			A.        Bank and Borrower have entered into that certain Loan and Security Agreement dated as of August 28, 2012, as amended by that certain First Amendment to Loan and Security Agreement dated as of January 31, 2014, by and between Borrower and Bank, as amended by that certain Assumption and Second Amendment to Loan and Security Agreement (the “Second Amendment”) dated as of August 12, 2014, by and between Borrower and Bank, as amended by that certain Third Amendment to Loan and Security Agreement dated as of September 25, 2014, by and between Borrower and Bank, as further amended by that certain Fourth Amendment to Loan and Security Agreement dated as of October 31, 2014, by and between Borrower and Bank, as further amended by that certain Consent and Fifth Amendment to Loan and Security Agreement dated as of December 31, 2015, by and between Borrower and Bank, and as further amended by that certain Consent and Sixth Amendment to Loan and Security Agreement dated as of January 9, 2018 (as the same may from time to time be further amended, modified, supplemented or restated, the “Loan Agreement”).
		

		
			B.         Bank has extended credit to Borrower for the purposes permitted in the Loan Agreement.
		

		
			C.        Borrower has requested that Bank amend the Loan Agreement to (i) revise an Event of Default and (ii) make certain revisions to the Loan Agreement as more fully set forth herein.
		

		
			D.        Bank has agreed to so amend certain provisions of the Loan Agreement, but only to the extent, in accordance with the terms, subject to the conditions and in reliance upon the representations and warranties set forth below.
		

		
			AGREEMENT
		

		
			NOW, THEREFORE, in consideration of the foregoing recitals and other good and valuable consideration, the receipt and adequacy of which is hereby acknowledged, and intending to be legally bound, the parties hereto agree as follows:
		

		
			1.        Definitions.  Capitalized terms used but not defined in this Amendment shall have the meanings given to them in the Loan Agreement.
		

		
			2.        Amendment to Loan Agreement.
		

		
			2.1       Section 5 (Events of Default).  Section 5 of the Loan Agreement is
		

		
			
		

		
			

		 

		

			1

		

 

		

		
			amended by deleting the text “March 31, 2018” appearing in subsection (xi) thereof, and inserting in lieu thereof the text “August 1, 2018”.
		

		
			3.         Limitation of Amendment.
		

		
			3.1       The amendment set forth in Section 2, above, is effective for the purpose set forth herein and shall be limited precisely as written and shall not be deemed to (a) be a consent to any amendment, waiver or modification of any other term or condition of any Loan Document, or (b) otherwise prejudice any right or remedy which Bank may now have or may have in the future under or in connection with any Loan Document.
		

		
			3.2       This Amendment shall be construed in connection with and as part of the Loan Documents and all terms, conditions, representations, warranties, covenants and agreements set forth in the Loan Documents, except as herein amended, are hereby ratified and confirmed and shall remain in full force and effect.
		

		
			4.         Representations and Warranties.  To induce Bank to enter into this Amendment, Borrower hereby represents and warrants to Bank as follows:
		

		
			4.1       Immediately after giving effect to this Amendment (a) the representations and warranties contained in the Loan Documents are true, accurate and complete in all material respects as of the date hereof (except to the extent such representations and warranties relate to an earlier date, in which case they are true and correct as of such date), and (b) no Event of Default has occurred and is continuing;
		

		
			4.2       Borrower has the power and authority to execute and deliver this Amendment and to perform its obligations under the Loan Agreement, as amended by this Amendment;
		

		
			4.3       The organizational documents of Borrower delivered to Bank on the Second Amendment Effective Date remain true, accurate and complete and have not been amended, supplemented or restated and are and continue to be in full force and effect, except as set forth on Exhibit 2 annexed to the Second Amendment;
		

		
			4.4       The execution and delivery by Borrower of this Amendment and the performance by Borrower of its obligations under the Loan Agreement, as amended by this Amendment, have been duly authorized;
		

		
			4.5       The execution and delivery by Borrower of this Amendment and the performance by Borrower of its obligations under the Loan Agreement, as amended by this Amendment, do not and will not contravene (a) any law or regulation binding on or affecting Borrower, (b) any contractual restriction with a Person binding on Borrower, (c) any order, judgment or decree of any court or other governmental or public body or authority, or subdivision thereof, binding on Borrower, or (d) the organizational documents of Borrower;
		

		
			4.6       The execution and delivery by Borrower of this Amendment and the performance by Borrower of its obligations under the Loan Agreement, as amended by this Amendment, do not require any order, consent, approval, license, authorization or validation of,
		

		
			
		

		
			

		 

		

			2

		

 

		

		
			or filing, recording or registration with, or exemption by any governmental or public body or authority, or subdivision thereof, binding on Borrower, except as already has been obtained or made; and
		

		
			4.7       This Amendment has been duly executed and delivered by Borrower and is the binding obligation of Borrower, enforceable against Borrower in accordance with its terms, except as such enforceability may be limited by bankruptcy, insolvency, reorganization, liquidation, moratorium or other similar laws of general application and equitable principles relating to or affecting creditors’ rights.
		

		
			5.         Updated Schedule D.   Borrower has delivered an updated Schedule D (Statement of Borrower’s Information) to the Loan Agreement in connection with this Amendment attached hereto as Exhibit 1 (the “Updated Schedule D”), which Updated Schedule D shall supersede in all respects that certain Schedule D (Statement of Borrower’s Information) to the Loan Agreement previously delivered by Borrower to Bank in connection with the Second Amendment.  Borrower agrees that all references in the Loan Agreement to “Schedule D” shall hereinafter be deemed to be a reference to the Updated Schedule D.
		

		
			6.         Integration.  This Amendment and the Loan Documents represent the entire agreement about this subject matter and supersede prior negotiations or agreements.  All prior agreements, understandings, representations, warranties, and negotiations between the parties about the subject matter of this Amendment and the Loan Documents merge into this Amendment and the Loan Documents.
		

		
			7.         Counterparts.  This Amendment may be executed in any number of counterparts and all of such counterparts taken together shall be deemed to constitute one and the same instrument.
		

		
			8.         Effectiveness.  This Amendment shall be deemed effective upon (a) the due execution and delivery to Bank of this Amendment by each party hereto and (b) Borrower’s payment of Bank’s legal fees and expenses incurred in connection with this Amendment.
		

		
			[Signature page follows.]
		

		
			 
		

		
			 
		

		
			

		 

		

			3

		

 

		

			 

		

		

		
			IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be duly executed and delivered as a sealed instrument under the laws of the Commonwealth of Massachusetts as of the date first written above.
		

			
					
						 

					
					
						 

					
					
						 

				
	
					
						 

					
					
						 

				
	
					
						 

					
					
						 

				
	
					
						BANK

					
					
						 

				
	
					
						 

					
					
						 

				
	
					
						SILICON VALLEY BANK

					
					
						 

				
	
					
						 

					
					
						 

				
	
					
						 

					
					
						 

				
	
					
						By:

					
					
						 

					
					
						 

				
	
					
						Name:

					
					
						 

					
					
						 

				
	
					
						Title:

					
					
						 

					
					
						 

				
	
					
						 

					
					
						 

				
	
					
						 

					
					
						 

				
	
					
						BORROWER

					
					
						 

				
	
					
						 

					
					
						 

				
	
					
						COLLEGIUM PHARMACEUTICAL, INC.

					
					
						 

				
	
					
						 

					
					
						 

				
	
					
						 

					
					
						 

				
	
					
						By:

					
					
						 

					
					
						 

				
	
					
						Name:

					
					
						 

					
					
						 

				
	
					
						Title:

					
					
						 

					
					
						 

				
	
					
						 

					
					
						 

				

		
			 
		

		
			 
		

		
			

		 

		

			 

		

 

		

		
			EXHIBIT 1
		

		
			 
		

		
			
		

		
			

		 

		

			 

		

 

		

			 

		

		

		
			SCHEDULE D
		

		
			STATEMENT OF BORROWER’S INFORMATION
		

		
			Borrower hereby represents and warrants, as of the date of the Agreement, subject to any updates provided to Bank as required under the Agreement:  (If none, please indicate so.  Attach additional pages, if necessary.)
		

		
			*1.         The exact legal name of Borrower, as set forth in its formation documents, is: Collegium Pharmaceutical, Inc.
		

		
			*2.         Borrower currently operates and has operated during the previous five years under only the following names: Collegium Pharmaceutical, Inc., a Virginia corporation, and Collegium Pharmaceutical, Inc., a Delaware corporation.
		

		
			*3.         Borrower is organized in the Commonwealth of Virginia and is qualified to do business in the following states:  Massachusetts.
		

		
			*4.         The following are all of Borrower’s Subsidiaries and their respective states (or countries, if other than the U.S.) and dates of formation, as well as the percentage of total capital stock owned by Borrower:
		

			
					
						 

					
					
						 

					
					
						 

					
					
						 

				
	
					
						Name of Subsidiary

					
					
						State

					
					
						Date of 

					
						Formation

					
					
						Percentage of 
Total Capital Stock 
Owned by Borrower

				
	
					
						Collegium NF, LLC

					
					
						Delaware

					
					
						December 1, 2017

					
					
						100%

				
	
					
						Collegium Securities Corporation

					
					
						Massachusetts

					
					
						December 22, 2015

					
					
						100%

				

		
			 
		

		
			**5.        The following are all actions, suits, proceedings and investigations pending, or to Borrower’s knowledge, currently threatened by or against Borrower, in which a likely adverse decision could reasonably be expected to cause a Material Adverse Change in Borrower’s business, operations or financial condition:
		

		
			None, other than the following matters, each of which has been publicly disclosed: (i) defense of patent infringement litigation initiated by Purdue Pharma, L.P. in relation to Xtampza ER (case numbers 1:17-CV-11923-FDS (D. Mass. Oct.6, 2017) , 1:17-CV-11814-FDS (D. Mass. Sept. 21, 2017), and 1:15-CV-13099-FDS (D. Mass. Aug. 6, 2015)); (ii) defense of patent infringement litigation initiated by Purdue Pharma, L.P. in relation to Nucynta ER and IR (case number 1:18-CV-00226 (D. Del. Feb. 7, 2018)); and (iii) patent infringement litigation initiated by Collegium Pharmaceutical, Inc. against Teva Pharmaceutical USA, Inc. in relation to infringement of Collegium intellectual property (case number 1:18-CV-00300 FDS (D. Del. Feb. 22, 2018)).
		

		
			**6.        The following is a description of all returns, recoveries, disputes and claims of at least $50,000 each, received by Borrower within the last thirty (30) days:
		

		
			None
		

		
			
		

		
			

		 

		

			-3-

		

 

		

			 

		

		

		
			***7.       The following are all of Borrower’s copyrights or mask works registered with the United States Copyright Office:
		

		
			None
		

		
			****8.     The following are all of Borrower’s patents, trademarks and service marks, and all applications filed by Borrower in the United States Patent & Trademark Office for a patent or to register a trademark or service mark:
		

		
			See Exhibit A to this Schedule D.
		

		
			9.          The following is all of the Borrower’s indebtedness existing as of the date of the Agreement (other than indebtedness arising under the Agreement):
		

		
			None
		

		
			10.        The following is all of the Borrower’s investments (other than Subsidiaries) existing as of the date of the Agreement:
		

		
			None
		

		
			11.        The following are all liens to which Borrower’s assets and property are subject as of the date of the Agreement (other than liens in favor of Lender):
		

		
			None
		

		
			12.        Other exceptions to representations and warranties under Section 3 of the Agreement:
		

		
			None
		

		
			Borrower must update Bank of any material change to information:
		

			
					
						 

					
					
						 

					
					
						 

				
	
					
						*

					
					
						  

					
					
						at least thirty (30) days’ prior to the date of occurrence of the event necessitating such update.

				
	
					
						**

					
					
						 

					
					
						within five (5) days’ of the date of occurrence of the event necessitating such update.

				
	
					
						***

					
					
						 

					
					
						at least 15 days’ prior to the date of filing of any application with the United States Copyright Office.

				
	
					
						****

					
					
						 

					
					
						at least 30 days’ prior to the date of filing of any application with the United States Patent and Trademark Office.

				

		
			 
		

		
			
		

		
			

		 

		

			-4-

		

 

		

			 

		

		

		
			EXHIBIT A TO SCHEDULE D
		

		
			Borrower’s patents, trademarks and service marks, and all applications filed by Borrower in the United States Patent & Trademark Office for a patent or to register a trademark or service mark
		

			
					
						 

					
					
						 

					
					
						 

					
					
						 

					
					
						 

					
					
						 

					
					
						 

				
	
					
						Country

					
					
						Case Status

					
					
						Application No.

					
					
						Application Date

					
					
						Patent No. 

					
					
						Grant Date

					
					
						Title/Mark

				
	
					
						United States of America

					
					
						Granted

					
					
						10/614,866

					
					
						7/7/2003

					
					
						7,399,488

					
					
						7/15/2008

					
					
						ABUSE-DETERRENT PHARMACEUTICAL COMPOSITIONS OF OPIODS AND OTHER DRUGS

				
	
					
						United States of America

					
					
						Granted

					
					
						11/149,867

					
					
						6/10/2005

					
					
						7,771,707

					
					
						8/10/2010

					
					
						ABUSE-DETERRENT DRUG FORMULATIONS

				
	
					
						United States of America

					
					
						Granted

					
					
						12/823,628

					
					
						6/25/2010

					
					
						8,449,909

					
					
						5/28/2013

					
					
						ABUSE-DETERRENT DRUG FORMULATIONS

				
	
					
						United States of America

					
					
						Granted

					
					
						12/473,073

					
					
						5/27/2009

					
					
						8,557,291

					
					
						10/15/2013

					
					
						ABUSE-DETERRENT PHARMACEUTICAL COMPOSITIONS OF OPIOIDS AND OTHER DRUGS

				
	
					
						United States of America

					
					
						Granted

					
					
						13/870,690

					
					
						4/25/2013

					
					
						8,758,813

					
					
						6/24/2014

					
					
						ABUSE-DETERRENT DRUG FORMULATIONS

				
	
					
						United States of America

					
					
						Granted

					
					
						12/965,572

					
					
						12/10/2010

					
					
						8,840,928

					
					
						9/23/2014

					
					
						TAMPER-RESISTANT PHARMACEUTICAL COMPOSITIONS OF OPIODS AND OTHER DRUGS

				
	
					
						United States of America

					
					
						Granted

					
					
						13/551,455

					
					
						7/17/2012

					
					
						9,044,398

					
					
						6/2/2015

					
					
						ABUSE-DETERRENT PHARMACEUTICAL COMPOSITIONS OF OPIOIDS AND OTHER DRUGS

				
	
					
						United States of America

					
					
						Granted

					
					
						14/054,513

					
					
						10/15/2013

					
					
						9,248,195

					
					
						2/2/2016

					
					
						ABUSE-DETERRENT PHARMACEUTICAL COMPOSITIONS OF OPIOIDS AND OTHER DRUGS

				
	
					
						United States of America

					
					
						Granted

					
					
						14/946,275

					
					
						11/19/2015

					
					
						9,592,200

					
					
						3/14/2017

					
					
						ABUSE-DETERRENT PHARMACEUTICAL COMPOSITIONS OF OPIOIDS AND OTHER DRUGS

				

		
			 
		

		
			
		

		

		 

		

			-5-

		

 

		

			 

		

	
					
						

					
						 

					
					
						 

					
					
						 

					
					
						 

					
					
						 

					
					
						 

					
					
						 

				
	
					
						Country

					
					
						Case Status

					
					
						Application No.

					
					
						Application Date

					
					
						Patent No. 

					
					
						Grant Date

					
					
						Title/Mark

				
	
					
						United States of America

					
					
						Granted

					
					
						14/320,086

					
					
						6/30/2014

					
					
						9,682,075

					
					
						6/20/2017

					
					
						TAMPER-RESISTANT PHARMACEUTICAL COMPOSITIONS OF OPIODS AND OTHER DRUGS

				
	
					
						United States of America

					
					
						Granted

					
					
						15/255,859

					
					
						9/2/2016

					
					
						9,737,530

					
					
						8/22/2017

					
					
						PROCESS OF MAKING STABLE ABUSE-DETERRENT ORAL FORMULATIONS

				
	
					
						United States of America

					
					
						Granted

					
					
						14/147,088

					
					
						1/3/2014

					
					
						9,763,883

					
					
						9/19/2017

					
					
						ABUSE-DETERRENT DRUG FORMULATIONS

				
	
					
						United States of America

					
					
						Pending

					
					
						14/321,125

					
					
						7/1/2014

					
					
						 

					
					
						 

					
					
						TAMPER-RESISTANT PHARMACEUTICAL COMPOSITIONS OF OPIOIDS AND OTHER DRUGS

				
	
					
						United States of America

					
					
						Pending

					
					
						15/606,112

					
					
						5/26/2017

					
					
						 

					
					
						 

					
					
						TAMPER-RESISTANT PHARMACEUTICAL COMPOSITIONS OF OPIODS AND OTHER DRUGS

				
	
					
						United States of America

					
					
						Pending

					
					
						15/725,818

					
					
						10/5/2017

					
					
						 

					
					
						 

					
					
						ABUSE-DETERRENT PHARMACEUTICAL COMPOSITIONS OF OPIOIDS AND OTHER DRUGS

				
	
					
						United States of America

					
					
						Pending

					
					
						15/727,134

					
					
						10/6/2017

					
					
						 

					
					
						 

					
					
						ABUSE-DETERRENT PHARMACEUTICAL COMPOSITIONS OF OPIOIDS AND OTHER DRUGS

				
	
					
						United States of America

					
					
						Pending

					
					
						15/681,589

					
					
						8/21/2017

					
					
						 

					
					
						 

					
					
						ABUSE-DETERRENT DRUG FORMULATIONS

				
	
					
						United States of America

					
					
						Pending

					
					
						15/649,024

					
					
						7/13/2017

					
					
						 

					
					
						 

					
					
						PROCESS OF MAKING STABLE ABUSE-DETERRENT ORAL FORMULATIONS

				
	
					
						United States of America

					
					
						 Pending

					
					
						15/699,229

					
					
						9/8/2017

					
					
						 

					
					
						 

					
					
						METHOD OF TREATMENT WITH OXYCODONE FORMULATIONS HAVING FOOD EFFECTS

				

		
			 
		

		
			
		

		

		 

		

			-6-

		

 

		

			 

		

	
					
						

					
						Trademarks and Trademark Applications

					
					
						 

					
					
						 

					
					
						 

					
					
						 

					
					
						 

					
					
						 

				
	
					
						Name

					
					
						Application

					
						Date

					
					
						Application

					
						Number

					
					
						Publication

					
						Date

					
					
						Registration

					
						Date

					
					
						Registration

					
						Number

					
					
						Status

				
	
					
						Collegium

					
						Pharmaceutical

					
					
						10/17/2014

					
					
						86/426952

					
					
						2/10/2015

					
					
						6/6/2017

					
					
						5218890

					
					
						Registered

				
	
					
						DeterX

					
					
						9/19/2007

					
					
						77/283090

					
					
						6/17/2008

					
					
						9/27/2011

					
					
						4031851

					
					
						Allowed

				
	
					
						Xtampza 

					
					
						2/5/2015

					
					
						86/525672

					
					
						6/23/2015

					
					
						8/23/2016

					
					
						5027886

					
					
						Registered

				

		
			 
		

		 

		

			-7-Exhibit 10.1

 

May 8, 2018

 

Mr. Michael S. Burke
 1999 Avenue of the Stars, Suite 2600
 Los Angeles, CA 90071

 

Re: Post-Employment Health Insurance Benefit

 

Dear Mike:

 

The purpose of this letter is to memorialize AECOM’s offer of certain health insurance benefits to you and your eligible dependents in the event of your departure from the Company.

 

Subject to the terms and conditions enumerated below, in the event your employment is terminated by AECOM for any reason other than Cause, or by you for Good Reason, or due to your Retirement or Total and Permanent Disablement(1) (each of the preceding circumstances is hereinafter referred to as a “Status Change”), AECOM shall provide to you and your eligible dependents coverage under the Company’s employee health insurance plans, including medical, dental, vision and prescription benefits (hereinafter “the Plans”) subject to the following terms and conditions:

 

1.              Subject to paragraph 6 of this letter, for the first twenty-four (24) months following a Status Change, AECOM shall pay the Company’s and your and your eligible dependents’ portion of the premium(s) for coverage under the Plans as well as for coverage under the Executive Medical Reimbursement Plan (EMRP).

 

2.              Subject to paragraph 6 of this letter, commencing on the twenty-fifth (25th) month following the Status Change, the Company shall provide to you and your eligible dependents coverage under the Plans at your (or your dependents’) expense at the active employee group rates in effect at the 25th month following the Status Change, and as adjusted from time to time for active employees.

 

3.              All contributions by AECOM to the insurance premiums for you and your dependents as outlined above will be reported as taxable income and subject to applicable taxes, deductions and withholding.

 

4.              If you are enrolled in the Plans upon reaching age 65, you agree to enroll in Medicare, at which point Medicare shall be primary to the coverage provided by AECOM’s health insurance program. In addition, if your spouse is enrolled in the Plans upon reaching age 65, she too will enroll in Medicare, at which point Medicare shall be primary to coverage provided by AECOM’s health insurance program.  AECOM’s health insurance programs will coordinate coverage with Medicare regardless of whether you and/or your spouse have enrolled in Medicare.

 

(1)  The terms “Cause”, “Good Reason”, “Retirement” and “Total and Permanent Disablement” shall have the meanings assigned to them in the Compensation Letter Agreement, dated March 6, 2014, between you and AECOM (“the Letter Agreement”).

 

 

5.              Coverage for you and your eligible dependents shall be provided under the Company insurance plans available to employees and subject to the terms and conditions of said plans.

 

6.              Notwithstanding any other provision of this letter to the contrary, AECOM’s obligation to continue to provide coverage to you and your eligible dependents following the Status Change shall cease upon the earlier of (i) the date you and/or your eligible dependents become eligible for comparable health insurance coverage offered by another entity or employer; or (ii) with respect to each of your dependents, the date upon which your dependent ceases to be eligible for coverage under the terms of the Plans.

 

7.              Subject to the terms of paragraph 6, during your lifetime, coverage under AECOM’s health insurance program shall be extended to you and your eligible dependents who were covered under the Plans at the time of the Status Change.  In the event of your death, if your spouse at the time of the Status Change (“Surviving Spouse”) continues to be covered under the Plans at the time of your death, such coverage shall continue to be available to your Surviving Spouse at her expense but at the Company’s group rates, for her lifetime and subject to the terms and conditions set forth in this letter.

 

8.              To the extent the Company finds it impossible or impermissible under applicable law to provide the coverage described above under its group health insurance policies, the Company shall provide to you or your Surviving Spouse a monthly cash payment equivalent to the Company’s monthly contribution toward the health insurance premium for active employees in effect at the time continued coverage becomes impossible or impermissible.  Such cash payment shall be subject to the identical terms and conditions hereinabove described with respect to coverage under the Plans.  All such payments will be reported as taxable income and subject to applicable taxes, deductions, and withholding.

 

9.              The foregoing coverage shall satisfy the obligations of the Company and its health insurance programs to you and your eligible dependents under the Comprehensive Omnibus Reconciliation Act of 1985, as amended (“COBRA”) and any analogous state laws, and you agree to make any elections requested by the Company to evidence such fact.

 

10.       For purposes of this Letter, the term “spouse” or “surviving spouse” shall refer to the spouse to whom you are married at the time of the Status Change.”

 

11.       The health insurance benefits outlined in this letter shall replace and supersede the post-employment insurance benefit set forth in paragraph 2 of the “Severance” section of the Letter Agreement.

 

2

 

All other provisions and terms and conditions of the Letter Agreement not specifically addressed herein shall continue to apply in full force and effect.

 

Acceptance

 

Please acknowledge your agreement with the terms set forth in this letter by signing in the designated space below. A copy of this letter is enclosed for your records.

 

 

Sincerely,

 

 

	
/s/ James H. Fordyce
    	
 
    	
 
    
	
James H. Fordyce, Lead Director
    	
 
    	
 
    
	
Compensation/Organization Committee Chair
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
ACCEPTED:
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
/s/ Michael S. Burke
    	
 
    	
May 8, 2018
    
	
Michael S. Burke
    	
 
    	
Date
    
	
Chairman and Chief Executive Officer
    	
 
    	
 
    

 

3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00283-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00283-of-00352.parquet"}]]